90 related articles for article (PubMed ID: 10658923)
1. Tritiated kappa receptor antagonist norbinal torphimine: synthesis and in vitro binding in three different tissues.
Márki A; Otvös F; Tóth G; Hosztafi S; Borsodi A
Life Sci; 2000; 66(1):43-9. PubMed ID: 10658923
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
3. Selective opioid receptor agonist and antagonist displacement of [3H]naloxone binding in amphibian brain.
Newman LC; Wallace DR; Stevens CW
Eur J Pharmacol; 2000 Jun; 397(2-3):255-62. PubMed ID: 10844122
[TBL] [Abstract][Full Text] [Related]
4. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
[TBL] [Abstract][Full Text] [Related]
5. Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays.
Márki A; Monory K; Otvös F; Tóth G; Krassnig R; Schmidhammer H; Traynor JR; Roques BP; Maldonado R; Borsodi A
Eur J Pharmacol; 1999 Oct; 383(2):209-14. PubMed ID: 10585536
[TBL] [Abstract][Full Text] [Related]
6. The in vitro pharmacological characterization of naloxone benzoylhydrazone.
Berzetei-Gurske IP; White A; Polgar W; DeCosta BR; Pasternak GW; Toll L
Eur J Pharmacol; 1995 Apr; 277(2-3):257-63. PubMed ID: 7493617
[TBL] [Abstract][Full Text] [Related]
7. Selective kappa-opioid antagonists related to naltrindole. Effect of side-chain spacer in the 5'-amidinoalkyl series.
Jales AR; Husbands SM; Lewis JW
Bioorg Med Chem Lett; 2000 Oct; 10(20):2259-61. PubMed ID: 11055333
[TBL] [Abstract][Full Text] [Related]
8. Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
J Med Chem; 1998 Dec; 41(25):4911-4. PubMed ID: 9836606
[No Abstract] [Full Text] [Related]
9. BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
Broom DC; Guo L; Coop A; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):1195-200. PubMed ID: 10945877
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship of N17'-substituted norbinaltorphimine congeners. Role of the N17' basic group in the interaction with a putative address subsite on the kappa opioid receptor.
Portoghese PS; Lin CE; Farouz-Grant F; Takemori AE
J Med Chem; 1994 May; 37(10):1495-500. PubMed ID: 8182708
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and binding characteristics of tritiated TIPP[psi], a highly specific and stable delta opioid antagonist.
Nevin ST; Tóth G; Weltrowska G; Schiller PW; Borsodi A
Life Sci; 1995; 56(10):PL225-30. PubMed ID: 7885186
[TBL] [Abstract][Full Text] [Related]
12. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
13. The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats.
Jewett DC; Grace MK; Jones RM; Billington CJ; Portoghese PS; Levine AS
Brain Res; 2001 Aug; 909(1-2):75-80. PubMed ID: 11478923
[TBL] [Abstract][Full Text] [Related]
14. The role of the side chain in determining relative delta- and kappa-affinity in C5'-substituted analogues of naltrindole.
Black SL; Jales AR; Brandt W; Lewis JW; Husbands SM
J Med Chem; 2003 Jan; 46(2):314-7. PubMed ID: 12519069
[TBL] [Abstract][Full Text] [Related]
15. Importance of phenolic address groups in opioid kappa receptor selective antagonists.
Thomas JB; Fix SE; Rothman RB; Mascarella SW; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 2004 Feb; 47(4):1070-3. PubMed ID: 14761209
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pharmacological evaluation of [(3)H]HS665, a novel, highly selective radioligand for the kappa opioid receptor.
Guerrieri E; Mallareddy JR; Tóth G; Schmidhammer H; Spetea M
ACS Chem Neurosci; 2015 Mar; 6(3):456-63. PubMed ID: 25496417
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological effects of naltriben as a ligand for opioid mu and kappa receptors in rat cerebral cortex.
Kim KW; Son Y; Shin BS; Cho KP
Life Sci; 2001 Feb; 68(11):1305-15. PubMed ID: 11233997
[TBL] [Abstract][Full Text] [Related]
18. Irreversible labelling of the opioid receptors by a melphalan-substituted [Met5]enkephalin-Arg-Phe derivative.
Sartania N; Szatmári I; Orosz G; Rónai AZ; Medzihradszky K; Borsodi A; Benyhe S
Eur J Pharmacol; 1999 Jun; 373(2-3):241-9. PubMed ID: 10414445
[TBL] [Abstract][Full Text] [Related]
19. Species differences in the stereoselectivity of kappa opioid binding sites for [3H]U-69593 and [3H]ethylketocyclazocine.
Benyhe S; Szücs M; Borsodi A; Wollemann M
Life Sci; 1992; 51(21):1647-55. PubMed ID: 1331638
[TBL] [Abstract][Full Text] [Related]
20. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor.
Remmers AE; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
J Pharmacol Exp Ther; 1999 Feb; 288(2):827-33. PubMed ID: 9918595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
